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Health Protection and Inﬂuenza Research Group, Division of Epidemiology and Public Health, University of Nottingham School of Medicine, City Hospital Campus,
Nottingham, UKAbstractAlthough the neuraminidase inhibitors (NIs), oseltamivir and zanamivir were ﬁrst licensed in 1999, their clinical effectiveness is still hotly debated.
Two rigorous systematic reviews and meta-analyses of the data from clinical trials conducted in community settings against relatively benign
inﬂuenza, both suggest that reductions in symptom duration are extremely modest, under one day. Whilst one of these reviews could ﬁnd
no evidence of reductions in complications, the most recent review reported clinically meaningful and statistically signiﬁcant reductions in
the likelihood of requiring antibiotics (44%) and hospitalizations (63%) in adult patients with conﬁrmed inﬂuenza, treated with oseltamivir. A
further meta-analysis of observational data from the 2009 inﬂuenza A(H1N1) pandemic suggested that, in hospitalised patients, NIs
signiﬁcantly reduced mortality in adults by 25% overall, and by 62% if started within 48 hours of symptom onset, compared with no
treatment. But, the effectiveness of NIs in children is far less clear. Taken together, these data suggest that NIs should be reserved for
patients with inﬂuenza who are at high-risk of complications, or when clinically assessed found to be markedly unwell, or rapidly
deteriorating. In such patients, treatment should be initiated empirically, as soon as possible, preferably with follow-on virological conﬁrmation.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: jvt@nottingham.ac.ukUp until 1999, inﬂuenza management involved vaccination for
primary prevention, and use of M2-inhibitors (amantadine and
rimantadine) for prophylaxis and treatment. The latter were
problematic medicines to use, owing to rapid emergence of
resistance (especially when used for treatment and prophylaxis
in the same setting and in immunocompromised patients) [1,2],
absence of activity against inﬂuenza B, and frequent central
nervous system side-effects (most often observed with aman-
tadine; e.g. anxiety, hallucinations, nightmares and confusion),
particularly in elderly subjects in whom the elimination half-life
may be doubled [3].
From 1999 onwards, the neuraminidase inhibitors (NIs),
zanamivir and oseltamivir, have offered new prospects forMicrobiol Infect 2015; 21: 222–225
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with, overall, a more benign side-effect proﬁle (albeit with a very
common reported incidence of headache and nausea for osel-
tamivir) [4]. Notwithstanding, up until the A(H1N1)pdm09
pandemic in 2009, adoption and usage of NIs had been low in all
territories except Japan. The ‘Achilles Heel’ of the NIs has always
been their rather modest effect on symptom reduction [4], and
somewhat limited historical evidence of their ability to reduce
complications [5]. The combination of needing rapid access to
treatment after symptom onset, and poor discriminatory powers
of physicians to distinguish inﬂuenza clinically from a variety of
other common respiratory virus infections, add further logistic
and clinical challenges [6–8]. Taken together, the latter two el-
ements could encourage inappropriate use of primary-care
services for non-serious, self-limiting respiratory virus in-
fections, produce logistic hurdles in terms of rapid access to
treatment, and result in NIs being used to ‘treat’ a variety of non-
inﬂuenza-related respiratory virus infections. The response of
guidance authorities to this clinical conundrum has, in general,European Society of Clinical Microbiology and Infectious Diseases
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where diagnostic certainty of inﬂuenza is enhanced, access to
treatment is timely, and the patient is less likely to have un-
complicated inﬂuenza infection [9]—essentially periods when
inﬂuenza is known to be circulating widely, and use in high-risk
patients who can be treated rapidly after symptom onset.
The above scenario was in sharp contrast to policy evolution
over use of NIs in the event of a pandemic. In this arena, in
2005, responding to the pandemic threat posed by avian
inﬂuenza A(H5N1) in particular, the WHO recommended the
establishment of a global stockpile of antiviral drugs [10]; and
recommended that countries with sufﬁcient resources should
also acquire individual national stockpiles [10]. These stockpiles
were subsequently deployed widely during the 2009 pandemic,
albeit not against A(H5N1) but the much less virulent A(H1N1)
pdm09 virus. In the aftermath of this event, further questions
have been raised about the rationale of stockpiling NIs for
pandemic usage, and their clinical effectiveness. Recent debate
has been polarized by an updated Cochrane review [11], which
has been used to suggest that NIs are hardly effective, and
should not be used or stockpiled; and a global individual
participant data (IPD) meta-analysis (the PRIDE study) sug-
gesting that NIs reduced mortality during the pandemic [12].
Where do such apparently disparate conclusions leave the
frontline microbiologist or infectious diseases physician in
terms of the management of patients, and the giving of advice to
others?
In the Summary of Product Characteristics, oseltamivir is stated
to reduce the duration of inﬂuenza symptoms by 1 day in adults
and 1.5 days in children [4], with similar ﬁgures for zanamivir
[13]. In the latest systematic review and meta-analysis of clinical
trials data performed by the Cochrane collaboration, these
modest effects were conﬁrmed; oseltamivir reduced time
to alleviation of symptoms of inﬂuenza-like illness in adults
by 16.8 h and by 29 h in children [11]. The authors of the
Cochrane review could ﬁnd no signiﬁcant effects on pneu-
monia, serious complications, hospitalizations or deaths, leading
them to state that ‘treatment trials do not settle the question
whether the complications of inﬂuenza (such as pneumonia) are
reduced, because of a lack of deﬁnitions’ [11]. Although the
Cochrane review identiﬁed 107 reports (some unpublished and
not previously made available) only 46 were included in the
meta-analysis. At least as importantly the clinical trials examined
were all conducted in the setting of ‘relatively benign inﬂuenza’
[11] in the community, which occurred during normal winter
seasonal periods. Under such circumstances it is difﬁcult to
determine if the absence of any statistically signiﬁcant effect
on complications amounts to evidence of no effect; or if in
fact sampling bias would have been the real issue because
of failure to use all of the available data, and a low frequencyClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
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study sample comprising relatively mild inﬂuenza cases.
An alternative analysis of the clinical trials data for oselta-
mivir treatment in adults has subsequently been published,
initiated by the Multi-party Group for Advice on Science
(MUGAS) Consortium [14]. Conducted independently of the
manufacturer, this new analysis considered all of the clinical
trials data for oseltamivir and adopted an IPD approach. Like
systematic reviews, an IPD analysis aims to summarize the ev-
idence from multiple studies investigating the same research
question. However, unlike a systematic review, which relies on
published estimates of treatment effect from various studies
that may not be directly comparable because of varying clinical
case deﬁnitions and treatment regimens, an IPD approach
collates individual patient-level data from the source studies,
and applies standard deﬁnitions and techniques to arrive at a
single pooled effect estimate [15]. Using such an IPD approach,
Dobson and colleagues showed that the reduction in time to
alleviation of inﬂuenza symptoms in adults was remarkably
similar to that described in the Cochrane review (which did not
use an IPD approach); but in sharp contrast, reductions in
lower respiratory tract complications requiring antibiotics
associated with oseltamivir treatment were clinically important
and highly signiﬁcant in both the intention-to-treat population
(38% reduction; p < 0.0001) and the intention-to-treat inﬂu-
enza-conﬁrmed population (44% reduction; p < 0.0001). More
importantly, hospitalizations were also signiﬁcantly reduced in
the intention-to-treat inﬂuenza-conﬁrmed population (63%
reduction; p = 0.013) but not in the intention-to-treat popu-
lation (39% reduction; p = 0.066). By using a superior meth-
odological technique, these new data offer a robust challenge to
the previous interpretation of the clinical trials data on osel-
tamivir in relation to the reduction in complications of public
health importance, since in most major healthcare systems
emergency hospitalization is a potent cost driver and there is an
imperative to reduce antibiotic usage. These new data under-
score the importance of treating high-risk patients (those at
elevated risk of hospitalization) with NIs if they present early
with symptoms of seasonal inﬂuenza.
Data derived from community settings and in the context of
relatively mild seasonal inﬂuenza are not easily generalizable to
hospitalized patients with severe inﬂuenza; or a pandemic sce-
nario in which a novel virus, combined with high levels of
population susceptibility, produce widespread morbidity and
mortality. Evidence to inform clinical decision-making in these
settings should ideally be derived from those settings; but in
both cases, randomized trials are unlikely to prove ethically
feasible, placing greater reliance on observational data. Obser-
vational studies are generally considered methodologically
inferior to experimental study designs that involve randomof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 222–225
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allocation ensures that treated and non-treated groups differ
only by chance, whether in terms of pre-existing comorbidities,
illness severity or other (measured or unmeasured) clinical
characteristics; typically this produces balanced arms that, in
turn, give greater conﬁdence that any observed differences in
outcomes can be attributed to treatment effects. On the other
hand, observational studies investigating treatment effects are
prone to ‘confounding by indication’ because real-life treatment
decisions are inﬂuenced by a patient’s clinical characteristics and
the attending physician’s behaviour; this means that there is less
certainty about attributing an observed outcome to treatment
effects. This is why a systematic review of published observa-
tional studies investigating the association between NI antiviral
use during the 2009 inﬂuenza pandemic and patient outcomes
only cautiously concluded that a statistically signiﬁcant 65%
mortality reduction in early treated versus untreated patients
suggested a meaningful public health beneﬁt [16]. Recent de-
velopments in methodological approaches, such as propensity
scoring, make it possible to use observational data for evaluating
treatment effects with greater conﬁdence; however, they can
only be used when detailed individual level data on patient
characteristics are available. Propensity scores are a statistical
method of addressing confounding by indication when investi-
gating treatment effects; essentially, they predict the likelihood
of treatment based on a speciﬁed set of patient characteristics
[17]. Once propensity scores have been calculated, researchers
can adjust for varying treatment propensity or match study
subjects on propensity scores to create more equivalent groups
that approximate to randomly allocated treatment groups in a
randomized controlled trial. A limitation of propensity scoring
methods is that they can only account for known confounders
and if important covariates are omitted from the propensity
score derivation model, this will introduce a bias in the results.
The largest and most convincing study of observational data
from the 2009–10 pandemic period, using an IPD approach and
propensity scoring, provides further evidence that NIs reduced
mortality in patients hospitalized with pandemic inﬂuenza [12].
The study included 29 234 hospitalized subjects worldwide, of
whom 86% had laboratory-conﬁrmed A(H1N1)pdm09 infection
and showed that mortality in adults was reduced by 25% overall
(p = 0.0002, treatment at any time versus none), and by 62%
(p <0.0001) if treatment was started within 48 h of illness onset
[12]. But the ﬁndings were not statistically signiﬁcant in children.
Of further note, late treatment (48 h of symptom onset) of
adults requiring intensive care still resulted in amortality reduction
of 35% (p = 0.0183) [12]. Although the authors were careful to
adjust for treatment propensity, they acknowledged that residual
confounding by indication was possible given the source data
limitations. They were also unable to adjust completely for diseaseClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
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individual source studies. Time-dependent treatment effects can
also impact the analysis of observational data, such that treatment
can appear to be favourable compared with no treatment because
of ‘immortal time bias’ [18,19]—essentially, patients who die early
donot get anopportunity to receive treatment. In the PRIDE study
[12], the researchers used well-accepted techniques to account
for this potential bias by only considering survival time after
treatmentwas initiated in the treated group [19]. Such analyses still
cannot account fully for other time-dependent biases that may be
at play, such as delayed admission following illness onset; but, as of
now, there is no consensus among statisticians about the best
approach to deal with all these biases, simultaneously, in a single
statistical model. Notwithstanding, the PRIDE investigators sub-
sequently presented an array of results obtained from a number of
alternative statistical models, and all seem to support the conclu-
sion that NIs were associated with a signiﬁcant reduction in
mortality [20]. Therefore, in the absence of a randomized
controlled trial, this IPD analysis of observational data remains, to
date, the most methodologically robust evidence on NI effec-
tiveness in the context of patients hospitalized with inﬂuenza.
What then should microbiologists, infectious disease physi-
cians and pulmonologists advise in day-to-day practice? Taken
together, what advice can be summarized from the Cochrane
review [11], the analysis by Dobson and colleagues [14], and the
PRIDE study [12]? Most cases of inﬂuenza will be mild, and
managed in primary care without the use of viral diagnostic
tests or the involvement of secondary-care physicians. Here,
given the modest effect of NIs on reduction in symptom
duration observed consistently across two meta-analyses
[11,14], early treatment of inﬂuenza-like illness should be
emphasized for high-risk patients at elevated risk of hospitali-
zation, and other patients who are markedly unwell or obvi-
ously deteriorating; in both cases, NIs may well exert a
protective effect and avert hospitalizations or complications.
In hospitals, where patients admitted with inﬂuenza, by
deﬁnition, have severe infection and may already be several days
into the illness (after symptom onset), NI treatment should be
presumptive, based on clinical suspicion of inﬂuenza; and im-
mediate, with the emphasis on instigating therapy as early as
possible, without waiting for virological conﬁrmation. This
might occur alongside antibiotic treatment if a bacterial aeti-
ology cannot be ﬁrmly excluded, because bacterial pneumonia
is a frequent complication in patients who are hospitalized with
inﬂuenza [21]. If adequately taken respiratory specimens later
fail to conﬁrm inﬂuenza (or reveal an alternative virus aetiology)
NIs can be stopped at that juncture.
In terms of strengthening the evidence for the future, and
assuming, somewhat realistically, that randomized trials will not
be possible in patients with severe inﬂuenza, new studies needEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 222–225
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onset and progression, comorbidities, disease severity, treat-
ment (particularly NIs, corticosteroids and antibiotics, along
with detailed treatment regimens), outcomes such as inﬂuenza-
related pneumonia (with radiological and microbiological re-
sults), need for and duration of critical care, length of stay in
hospital, and inﬂuenza-related mortality; to facilitate more so-
phisticated survival analyses, exact dates of illness onset,
admission to various levels of care, start of treatment, diag-
nostic tests, outcomes and length of follow up are also required.
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